<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01741376</url>
  </required_header>
  <id_info>
    <org_study_id>1P50DA033942-01</org_study_id>
    <nct_id>NCT01741376</nct_id>
  </id_info>
  <brief_title>Progesterone and Atomoxetine for Cocaine Cessation</brief_title>
  <official_title>Progesterone and Atomoxetine for Cocaine Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the role of progesterone (a hormone found in both men&#xD;
      and women) on stopping cocaine use. The study will examine whether the medication, in&#xD;
      combination with behavior therapy will decrease cocaine use, cigarette smoking, withdrawal&#xD;
      symptoms, impulsivity and stress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    All clinical trials within the Department of Psychiatry at UMN were suspended and this study&#xD;
    was withdrawn due to no enrollment.&#xD;
  </why_stopped>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Cessation</measure>
    <time_frame>Days 1 to 86</time_frame>
    <description>Urine Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impulsivity</measure>
    <time_frame>Days 1 to 86</time_frame>
    <description>Self report of the following subjective questionnaires: (1) Behavioral Inhibition Activation Scales, (2) Barratt Impulsivity Scale, and (3) Brief Self Control Scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebos are given for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Progesterone (200 mg twice daily) and a placebo are given</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone 200 mg twice daily</description>
    <arm_group_label>Progesterone + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females between 18 and 45 and males between 18 and 60 years-of-age;&#xD;
&#xD;
          -  Understand the study procedures and provide written informed consent;&#xD;
&#xD;
          -  Meet DSM-IV criteria for cocaine or methamphetamine and nicotine dependence;&#xD;
&#xD;
          -  Minimum of cocaine use 4 days/months over last 3 months;&#xD;
&#xD;
          -  Minimum of 5 cigarettes/day for last twelve months;&#xD;
&#xD;
          -  Stable psychiatric status;&#xD;
&#xD;
          -  Stable medical status; Willing to use double-barrier contraception method if sexually&#xD;
             active and not surgically sterilized;&#xD;
&#xD;
          -  Regular menstrual cycles (for females);&#xD;
&#xD;
          -  No contraindications to progesterone treatment;&#xD;
&#xD;
          -  Ability to participate fully in research elements for the duration of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  DSM-IV diagnoses for current or lifetime psychotic disorders (unless substance&#xD;
             induced), bipolar disorder, current ADHD and other current substance dependence&#xD;
             (except nicotine dependence, or alcohol or cannabis dependence not exhibiting&#xD;
             withdrawal or other features requiring medical attention);&#xD;
&#xD;
          -  Currently using nicotine pharmacotherapy preparations;&#xD;
&#xD;
          -  history of thromboembolic events, diabetes, stroke, heart disease;&#xD;
&#xD;
          -  Psychotropic medications other than stable doses of anti-depressants;&#xD;
&#xD;
          -  Currently pregnant or nursing;&#xD;
&#xD;
          -  Liver enzyme levels three times normal limits;&#xD;
&#xD;
          -  Previous treatment with or adverse response to progesterone.&#xD;
&#xD;
          -  Serious suicide attempt within preceding 2 years;&#xD;
&#xD;
          -  Current use of exogenous hormones.&#xD;
&#xD;
          -  Conditions contraindicated to progesterone treatment (including, but not limited to,&#xD;
             thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding&#xD;
             disorders, heart disease, diabetes, history of stroke, allergy to peanuts,&#xD;
             hypersensitive to progesterone and liver dysfunction).&#xD;
&#xD;
          -  History of pheochromotytoma or narrow angle glaucoma,&#xD;
&#xD;
          -  Current hypertension, tachycardia or clinically relevant ECG abnormalites;&#xD;
&#xD;
          -  Allergy to peanuts,&#xD;
&#xD;
          -  Current suicidality or need for emergency psychiatric treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila M Specker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>November 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

